Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02064933 · ClinicalTrials.gov registry record
Patients Treated for Wiskott-Aldrich Syndrome (WAS) Since 1990
A clinical trial of Wiskott-Aldrich Syndrome, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- 305
- Enrollment target
- 20
- Study locations
NCT02064933 is a study of Wiskott-Aldrich Syndrome that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 305 participants, above the 34-participant average among 4 other Wiskott-Aldrich Syndrome trials with a reported enrollment target (797% higher). The trial reports 20 study locations across 15 states.
The verdict
NCT02064933, a study of Wiskott-Aldrich Syndrome, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- 305 participants
- Enrollment target
- 20
- Study locations
Study Summary
Wiskott - Aldrich syndrome (WAS) is a rare serious medical condition that causes problems both with the immune system and with easy bruising and bleeding. The immune abnormalities cause patients with WAS to be very susceptible to infections. Depending on the specific type of primary immune deficiency diseases, there are effective treatments, including antibiotics, cellular therapy and gene therapy, but studies of large numbers of patients are needed to determine the full range of causes, natural history, or the best methods of treatment for long term success. This multicenter study combines retrospective, prospective and cross-sectional analyses of the transplant experiences for patients with WAS who have already received HCT since 1990, or who will undergo Hematopoietic cell transplant (HCT) during the study period. The retrospective and prospective portions of the study will address the impact of a number of pre and post-transplant factors on post-transplant disease correction and ultimate benefit from HCT and the cross-sectional portion of the study will assess the benefit of HCT 2 years post-HCT in consenting surviving patients.
Conditions Studied
Study Locations (20)
California
- Cancer and Blood Disease Institute, Children's Hospital Los Angeles, Keck School of Medicine, University of Southern California - Los Angeles
- Department of Pediatrics, David Geffen School of Medicine at University of California, Los Angeles, - Los Angeles
- Lucile Salter Packard Children's Hospital at Stanford - Palo Alto
- University of California, San Francisco Benioff Children's Hospital - San Francisco
Minnesota
- Division of Pediatric Blood and Marrow Transplantation, University of Minnesota - Minneapolis
- Mayo Clinic Children's Center - Rochester
Missouri
- Cardinal Glennon Children's Hospital, Saint Louis University - St Louis
- Saint Louis Children's Hospital, Washington University - St Louis
Alabama
- Department of Pediatrics, University of Alabama at Birmingham - Birmingham
Arizona
- Phoenix Children's Hospital - Phoenix
Colorado
- Children's Hospital Denver, University of Colorado - Denver
Delaware
- Nemours Alfred I. duPont Hospital for Children - Wilmington
District of Columbia
- Children's National Hospital-George Washington University School of Medicine and Health Sciences - Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 305 participants |
| Start Date | 2014-02-02 |
| Est. Completion | 2019-05-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02064933
The ClinicalTrials.gov registry entry for NCT02064933 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 305 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 34-participant average among 4 other Wiskott-Aldrich Syndrome trials with a reported enrollment target (797% higher). The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Wiskott-Aldrich Syndrome appearing as the primary indexed condition, and to 0 interventions.
NCT02064933 reports 20 study locations spanning 15 distinct geographic areas - top geographies include California, Minnesota, Missouri.
Frequently Asked Questions
What is clinical trial NCT02064933 about?
NCT02064933 is a clinical study titled "Patients Treated for Wiskott-Aldrich Syndrome (WAS) Since 1990". Wiskott - Aldrich syndrome (WAS) is a rare serious medical condition that causes problems both with the immune system and with easy bruising and bleeding. The immune abnormalities cause patients with WAS to be very susceptible to infections. Depending on the specific type of primary immune deficienc...
What is the current status of trial NCT02064933?
This trial is currently completed. The enrollment target is 305 participants. The study started on 2014-02-02. Estimated completion is 2019-05-01.
What conditions does trial NCT02064933 study?
This clinical trial studies the following conditions: Wiskott-Aldrich Syndrome.
Who is sponsoring clinical trial NCT02064933?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02064933 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Delaware. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Wiskott-Aldrich Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Allogeneic Hematopoietic Stem Cell Transplant for Patients With Primary Immune Deficiencies
ACTIVE NOT RECRUITING · NA
-
Immune Disorder HSCT Protocol
ACTIVE NOT RECRUITING · Phase 2
-
A Clinical Study to Evaluate the Use of a Cryopreserved Formulation of OTL-103 in Subjects With Wiskott-Aldrich Syndrome
ACTIVE NOT RECRUITING · Phase 3
-
Efficacy, Safety and Pharmacokinetics of Gammaplex in Primary Immunodeficiency Diseases.
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.